Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Common Stock |
4.08M |
$38.4M |
$9.41 |
Oct 28, 2024 |
Direct |
Black Diamond Therapeutics, Inc. |
10%+ Owner |
Common Stock |
3.73M |
$23.6M |
$6.32 |
Aug 28, 2024 |
Direct |
Century Therapeutics, Inc. |
10%+ Owner |
Common Stock |
11.5M |
$17.1M |
$1.49 |
Aug 9, 2022 |
Direct |
Monte Rosa Therapeutics, Inc. |
10%+ Owner |
Common Stock |
1.57M |
$14.8M |
$9.41 |
Oct 29, 2024 |
Indirect |
LENZ Therapeutics, Inc. |
10%+ Owner |
Common Stock |
2.1M |
$8.57M |
$4.08 |
Mar 21, 2024 |
Direct |
Black Diamond Therapeutics, Inc. |
10%+ Owner |
Common Stock |
822K |
$5.2M |
$6.32 |
Aug 28, 2024 |
Indirect |
LENZ Therapeutics, Inc. |
10%+ Owner |
Common Stock |
842K |
$3.44M |
$4.08 |
Mar 21, 2024 |
Indirect |
Tempest Therapeutics, Inc. |
10%+ Owner |
Common Stock |
2.12M |
$2.33M |
$1.10 |
Aug 8, 2024 |
Indirect |
Century Therapeutics, Inc. |
10%+ Owner |
Common Stock |
714K |
$1.06M |
$1.49 |
Aug 9, 2022 |
Indirect |
Tempest Therapeutics, Inc. |
10%+ Owner |
Common Stock |
210K |
$231K |
$1.10 |
Aug 12, 2024 |
Direct |
Contineum Therapeutics, Inc. |
10%+ Owner |
Series B Preferred Stock |
1.74M |
|
|
Apr 9, 2024 |
Direct |
Contineum Therapeutics, Inc. |
10%+ Owner |
Series A-1 Preferred Stock |
1.42M |
|
|
Apr 9, 2024 |
Direct |
Contineum Therapeutics, Inc. |
10%+ Owner |
Series C Preferred Stock |
710K |
|
|
Apr 9, 2024 |
Indirect |
Contineum Therapeutics, Inc. |
10%+ Owner |
Series B Preferred Stock |
435K |
|
|
Apr 9, 2024 |
Indirect |
Contineum Therapeutics, Inc. |
10%+ Owner |
Class A Common Stock |
376K |
|
|
Apr 9, 2024 |
Direct |
Contineum Therapeutics, Inc. |
10%+ Owner |
Class A Common Stock |
148K |
|
|
Apr 9, 2024 |
Indirect |
Contineum Therapeutics, Inc. |
10%+ Owner |
Series A Preferred Stock |
9.25K |
|
|
Apr 9, 2024 |
Indirect |
Oyster Point Pharma, Inc. |
10%+ Owner |
Common Stock |
0 |
|
$11.20 |
Jan 3, 2023 |
Direct |
Oyster Point Pharma, Inc. |
10%+ Owner |
Common Stock |
0 |
|
$11.20 |
Jan 3, 2023 |
Indirect |